Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
CSPC Pharmaceutical Group ( (HK:1093) ) has shared an announcement.
CSPC Pharmaceutical Group has announced that its Prusogliptin and Metformin Extended-Release Tablets have received approval from China’s National Medical Products Administration to commence clinical trials. This product is the first fixed-dose combination of prusogliptin and metformin hydrochloride approved for such trials, aimed at treating adult patients with type 2 diabetes mellitus who have inadequate control with metformin alone. The approval marks a significant step in CSPC’s clinical development, offering a promising safety and tolerability profile compared to existing monotherapy options.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a company incorporated in Hong Kong, operating in the pharmaceutical industry. It focuses on developing and manufacturing pharmaceutical products, with a market focus on innovative drug formulations and therapies.
YTD Price Performance: 8.47%
Average Trading Volume: 29,601
Technical Sentiment Signal: Buy
Current Market Cap: $8.26B
For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue